Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 4/20 | 0.39 |
| ▸ | CTSD | P07339 | 2/20 | 0.39 |
| ▸ | REN | P00797 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.34 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30062703 | 0.89 | CALCRL (0.51) | OPRM1OPRD1CALCRLBACE1CTSD | |
| SCHEMBL30974462 | 0.88 | TERT (0.41) | CALCRLBACE1CTSDREN | |
| SCHEMBL29926499 | 0.85 | CALCRL (0.41) | OPRM1OPRD1CALCRLBACE1CTSD | |
| SCHEMBL30039158 | 0.84 | CTSD (0.38) | OPRM1OPRD1CALCRLBACE1CTSD | |
| SCHEMBL30353294 | 0.84 | CALCRL (0.49) | CALCRLBACE1 | |
| SCHEMBL30037378 | 0.83 | CALCRL (0.41) | CALCRLBACE1CTSDREN | |
| SCHEMBL30099495 | 0.82 | MEN1 (0.41) | REN | |
| SCHEMBL29388130 | 0.82 | TERT (0.41) | CALCRLBACE1REN | |
| SCHEMBL30454977 | 0.82 | CALCRL (0.43) | OPRM1OPRD1CALCRLRENOPRK1 | |
| SCHEMBL31518654 | 0.81 | TERT (0.42) | CALCRLRENKEAP1MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | Biocrucible Limited (GB) | 2026-05-05 | — | — | US | disclosed |
| US-20220112547-A1 | BIOCHEMICAL REACTION METHODS AND REAGENTS COMPRISING INTRINSICALLY DISORDERED REGIONS | Biocrucible Limited (GB) | 2022-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618102-B2 | Biochemical reaction methods and reagents comprising intrinsically disordered regions | POLM, POLR1A, POLR1E | OPRM1 4101/4885OPRD1 4566/4885CALCRL 1768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.